Lido Advisors LLC Buys 10,125 Shares of DexCom, Inc. $DXCM

Lido Advisors LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 43.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,324 shares of the medical device company’s stock after buying an additional 10,125 shares during the period. Lido Advisors LLC’s holdings in DexCom were worth $2,093,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC grew its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC lifted its position in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth boosted its holdings in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in DexCom by 1.4% during the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Benchmark reiterated a “buy” rating on shares of DexCom in a research note on Tuesday, June 23rd. Stifel Nicolaus set a $90.00 target price on DexCom and gave the stock a “buy” rating in a research note on Friday, June 5th. William Blair raised DexCom to a “strong-buy” rating in a report on Friday, May 15th. Barclays reaffirmed an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 price target on DexCom in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.36.

Insider Transactions at DexCom

In other news, EVP Jon Coleman sold 4,911 shares of DexCom stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $72.00, for a total transaction of $1,926,432.00. Following the sale, the insider owned 355,726 shares of the company’s stock, valued at approximately $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 71,750 shares of company stock valued at $5,163,241. Company insiders own 0.28% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $71.54 on Monday. The business has a 50-day moving average of $72.46 and a 200 day moving average of $68.95. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market cap of $27.61 billion, a P/E ratio of 30.57, a price-to-earnings-growth ratio of 1.18 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. As a group, research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.